{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:38:21Z","timestamp":1772134701944,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T00:00:00Z","timestamp":1394150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s13760-014-0285-z","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T09:25:00Z","timestamp":1394097900000},"page":"285-291","source":"Crossref","is-referenced-by-count":30,"title":["Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15\u00a0years"],"prefix":"10.1007","volume":"114","author":[{"given":"Hana","family":"Streitov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bare\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,7]]},"reference":[{"issue":"19","key":"285_CR1","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y (2008) Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70(19):1699\u20131706","journal-title":"Neurology"},{"issue":"16","key":"285_CR2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1212\/01.wnl.0000327601.46315.85","volume":"71","author":"M Hallett","year":"2008","unstructured":"Hallett M, Evinger C, Jankovic J, Stacy M (2008) BEBRF international workshop. Update on blepharospasm: report from the BEBRF international workshop. Neurology 71(16):1275\u20131282","journal-title":"Neurology"},{"key":"285_CR3","first-page":"751","volume":"64","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, Schwarz K, Donova DT (1990) Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatr 64:751\u2013757","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"8","key":"285_CR4","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/sj.eye.6702054","volume":"20","author":"E Ortisi","year":"2006","unstructured":"Ortisi E, Henderson HWA, Bunce C, Xing W, Collin JRO (2006) Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases. Eye 20(8):916\u2013922","journal-title":"Eye"},{"issue":"Suppl 1","key":"285_CR5","doi-asserted-by":"crossref","first-page":"I\/21","DOI":"10.1007\/PL00007813","volume":"248","author":"WH Jost","year":"2001","unstructured":"Jost WH, Kohl A (2001) Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 248(Suppl 1):I\/21\u2013I\/24","journal-title":"J Neurol"},{"key":"285_CR6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000008121","volume":"43","author":"JD Rollnik","year":"2000","unstructured":"Rollnik JD, Matzke M, Wohlfarth K, Dengler HB (2000) Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. Eur Neurol 43:9\u201312","journal-title":"Eur Neurol"},{"key":"285_CR7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/PL00007849","volume":"249","author":"R Cakmur","year":"2002","unstructured":"Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F (2002) Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 249:64\u201368","journal-title":"J Neurol"},{"issue":"1","key":"285_CR8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajo.2013.02.001","volume":"156","author":"CN Czyz","year":"2013","unstructured":"Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA (2013) Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol 156(1):173\u2013177","journal-title":"Am J Ophthalmol"},{"key":"285_CR9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1034\/j.1600-0404.2001.00109.x","volume":"103","author":"O Tucha","year":"2001","unstructured":"Tucha O, Naumann M, Berg D, Alders GL, Lange KW (2001) Quality of life in patients with blepharospasm. Acta Neurol Scand 103:49\u201352","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"285_CR10","first-page":"148","volume":"59\/92","author":"P Ka\u0148ovsk\u00fd","year":"1996","unstructured":"Ka\u0148ovsk\u00fd P, Bare\u0161 M, Streitov\u00e1 H, Posp\u00ed\u0161ilov\u00e1 D, Dufek M (1996) Socioeconomic aspects of the treatment of facial dyskinesias with botulinum toxin A. Czech Slov Neurol Neurochir 59\/92(3):148\u2013151","journal-title":"Czech Slov Neurol Neurochir"},{"issue":"4","key":"285_CR11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00702-007-0768-7","volume":"115","author":"C Kenney","year":"2008","unstructured":"Kenney C, Jankovic J (2008) Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 115(4):585\u2013591","journal-title":"J Neural Transm"},{"issue":"1","key":"285_CR12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0404.2004.00357.x","volume":"111","author":"J Reimer","year":"2005","unstructured":"Reimer J, Gilg K, Karow A, Esser J, Franke GH (2005) Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 111(1):64\u201370","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"285_CR13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1590\/S0004-27492006000500016","volume":"69","author":"CG Lasalvia","year":"2006","unstructured":"Lasalvia CG, Pereira Led S, da Cunha MC, Kitadai SP (2006) Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm. Arq Bras Oftalmol 69(5):701\u2013705","journal-title":"Arq Bras Oftalmol"},{"issue":"4","key":"285_CR14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","volume":"22","author":"C Colosimo","year":"2012","unstructured":"Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22(4):265\u2013273","journal-title":"Neurotox Res"},{"issue":"3","key":"285_CR15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11940-012-0169-6","volume":"14","author":"A Batla","year":"2012","unstructured":"Batla A, Stamelou M, Bhatia KP (2012) Treatment of focal dystonia. Curr Treat Options Neurol 14(3):213\u2013229","journal-title":"Curr Treat Options Neurol"},{"key":"285_CR16","author":"OH Ababneh","year":"2013","unstructured":"Ababneh OH, Cetinkaya A, Kulwin DR (2013) Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. doi: 10.1111\/ceo.12165","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"285_CR17","first-page":"95","volume":"22","author":"J Slawek","year":"2007","unstructured":"Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin A type A injections. Funct Neurol 22(2):95\u2013100","journal-title":"Funct Neurol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-014-0285-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-014-0285-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-014-0285-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T16:56:33Z","timestamp":1559494593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-014-0285-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,7]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1007\/s13760-014-0285-z","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,7]]}}}